Product Information
UZEDY ER 125 MG/0.35 ML SYRING is a brand product labeled by Teva Pharmaceuticals USA Inc., priced at $9329.0048 per ML under NDC 51759063010. Its NADAC has been published 124 times since May 22, 2024.
FDA first approved this application on Apr 28, 2023.
The High Outlier badge above means this manufacturer's average price in the risperidone market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
125 mg/.35mL
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
51759063010
Classification
Brand
Dosage Form
INJECTION, SUSPENSION, EXTENDED RELEASE
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
RISPERIDONEApproval Type
New Drug (NDA)
FDA Application
NDA213586FDA Approved
4/28/2023
On Market Since
5/1/2023
Pharmacological Classes
Price Statistics
The NADAC for UZEDY ER 125 MG/0.35 ML SYRING has been published 124 times since May 22, 2024, and over the history we have for it it has risen 6.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $9329.0048 per ML |
|---|---|
| All-time high | $9429.5841 (May 13, 2026) |
| All-time low | $8754.8057 (Nov 20, 2024) |
| 52-week high | $9429.5841 |
| 52-week low | $9066.3639 |
| Median price | $9066.3639 |
| Average price | $9070.4589 |
| Largest weekly change | +4.0% (Jan 7, 2026) |
| Weeks tracked | 124 |
| Tracking since | May 22, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the risperidone market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
risperidone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of UZEDY ER 125 MG/0.35 ML SYRING?
The current National Average Drug Acquisition Cost (NADAC) for UZEDY ER 125 MG/0.35 ML SYRING, manufactured by Teva Pharmaceuticals USA Inc., is $9329.0048 per ML (NDC 51759063010), effective Sep 30, 2026.
How has the price of UZEDY ER 125 MG/0.35 ML SYRING changed over time?
Over the history we have for it, the NADAC for UZEDY ER 125 MG/0.35 ML SYRING has risen 6.3%. It has been tracked across 124 weekly CMS publications since May 22, 2024.
What are the highest and lowest recorded NADAC prices for UZEDY ER 125 MG/0.35 ML SYRING?
Since May 22, 2024, the NADAC for UZEDY ER 125 MG/0.35 ML SYRING has ranged from a low of $8754.8057 (Nov 20, 2024) to a high of $9429.5841 (May 13, 2026), with a median of $9066.3639 per ML.
Are there cheaper alternatives to UZEDY ER 125 MG/0.35 ML SYRING?
No other NADAC-published product currently shares the active ingredient and strength of UZEDY ER 125 MG/0.35 ML SYRING in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures UZEDY ER 125 MG/0.35 ML SYRING?
UZEDY ER 125 MG/0.35 ML SYRING (NDC 51759063010) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a brand product.